To date, five Phase III studies have been initiated to evaluate various combinations of VEGF or VEGFR inhibitors plus either PD‐1 or PD‐L1 antibodies in patients with advanced RCC, of which three have been published (103, 105, 109). Here, PDCD1 is linked to renal cell carcinoma.